The section on FDA clinical trials and newly approved products provides a discussion of regulatory issues affecting regenerative medicine products.
An extensive Company Profiles section provides estimates for the revenues of the leading companies and a concise description of leading and emerging companies in the area of regenerative products for bones and joints, including product introductions, patents, and overall business strategies.
Both primary and secondary research methodologies were used to prepare this market research report. The base year for this study is 2012. Data for 2013 are estimated and 2018 is the forecast terminal year. Sales data are estimated in nominal dollars (unadjusted for inflation). Information to prepare this study was derived from market intelligence provided by leading companies involved in the regenerative medicine market. Data was accessed from government agencies and regulatory bodies that monitor and/or regulate medical devices. Searches of secondary material such as company annual reports and 10Ks, medical journal articles, prospectus assessments, government resources, and data from healthcare institutions were conducted.
The information and analyses presented in this report are based on an extensive survey of the biotechnology and pharmaceutical industries, as well as a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, pharmaceutical trade associations, and national and world health organizations.
Research analyst Kevin Gainer holds both B.A. and M.A. degrees in quantitative economic analysis, and has 25 years of economic and market research experience. He is the author of five publ
Copyright©2012 Vocus, Inc.
All rights reserved